TOLERABILITY OF TARGETED AGENTS IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)

被引：0
|
作者：
Su, Y. [1 ]
Shi, N. [2 ]
Landsman-Blumberg, P. [3 ]
Poehlein, C. [4 ]
Waxman, I. [5 ]
机构：
[1] Bristol Myers Squibb Co, Global Hlth Econ & Outcomes Res, Princeton, NJ USA
[2] Thomson Reuters Healthcare, Pharma Biotech, Cambridge, MA USA
[3] Thomson Reuters, Outcomes Res, Washington, DC USA
[4] Bristol Myers Squibb Co, Immunooncol, HQ Global Med Affairs, Princeton, NJ USA
[5] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：267 / 268
页数：2
相关论文
共 50 条
  • [1] FIRST-LINE TARGETED AGENTS AND COST OF CARE FOR PATIENTS WITH METASTATIC RENAL CELL CANCER (MRCC)
    Su, Y.
    Shi, N.
    Landsman-Blumberg, P.
    Poehlein, C.
    Waxman, I.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 269 - 270
  • [2] Tolerability of different first-line treatment (trt) regimens in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC)
    Mueller, L.
    Muench, A.
    Blumenstengel, K.
    Hutzschenreuther, U.
    Busies, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Tolerability of first-line therapy for metastatic renal cell carcinoma
    Porta, Camillo
    Szczylik, Cezary
    [J]. CANCER TREATMENT REVIEWS, 2009, 35 (03) : 297 - 307
  • [4] First-line treatment of metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Netsch, Christopher
    Gross, Andreas J. J.
    [J]. UROLOGIE, 2023, 62 (08): : 830 - 839
  • [5] Comparative effectiveness of combination first-line therapies for metastatic renal cell carcinoma (mRCC).
    Shay, Rebecca C.
    Nicklawsky, Andrew
    Lam, Elaine Tat
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Optimising first-line treatment for metastatic renal cell carcinoma
    Liang, Fei
    [J]. LANCET, 2020, 395 (10219): : E8 - E8
  • [7] Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC).
    Gore, M. E.
    Jones, R. J.
    Ravaud, A.
    Kuczyk, M.
    Demkow, T.
    Bearz, A.
    Laferriere, N.
    Strauss, U. P.
    Porta, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
    Barragan-Carrillo, Regina
    Chawla, Neal Shiv
    Salgia, Nicholas
    Meza, Luis A.
    Zengin, Zeynep Busra
    Li, Xiaochen
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Hsu, Joann
    Castro, Daniela V.
    Mercier, Benjamin D.
    Dorff, Tanya B.
    Tripathi, Abhishek
    Bergerot, Cristiane Decat
    Bergerot, Paulo Gustavo
    Chehrazi-Raffle, Alex
    Pal, Sumanta Kumar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS491 - TPS491
  • [9] Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States
    Benedict, A.
    Figlin, R. A.
    Charbonneau, C.
    Kreif, N.
    Hariharan, S.
    Negrier, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Gallardo, Jorge
    Lesovoy, Vladmir
    Al-Shukri, Salman
    Stus, Viktor
    Bair, A. H.
    Rosbrook, Brad
    Bycott, Paul W.
    Tarazi, Jamal Christo
    Kim, Sinil
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345